Cytokinin-binding proteins (67-kD CBP) were isolated from barley first leaves of 8–10-day-old plants and Arabidopsis thaliana rosette leaves of 9-week-old plants. A capability of these proteins for cytokinin binding was assessed from trans-zeatin competition with antiidiotypic antibodies (ABa-i) for complex formation with immobilized 67-kD CBP under competitive ELISA conditions. ABa-i were obtained against anti-trans-zeatin antibody. 67-kD CBP from A. thaliana and barley leaves, in combination with trans-zeatin, activated transcriptional elongation in the in vitro system containing chromatin and RNA polymerase I from the same leaves. A phenylurea derivative demonstrating a high cytokinin activity, N-phenyl-N1-(2-chloro-4-pyridyl)urea (4-PU-30) could not displace ABa-i from its complex with 67-kD CBP from either barley or A. thaliana leaves, which indicates the absence of its interaction with CBP. In the presence of 67-kD CBP, 4-PU-30 did not activate transcription in the in vitro system containing chromatin and RNA polymerase I from A. thaliana or barley leaves. This means that, as distinct from trans-zeatin, 4-PU-30 did not use 67-kD CBP for transcription activation. A. thaliana leaf preincubation in the 4-PU-30 solution for 1 h enhanced RNA synthesis in the transcriptional system containing chromatin and RNA polymerase I from these pretreated leaves. Thus, leaves recognized the 4-PU-30 signal using another receptor. 4-PU-30 capacity to retard leaf senescence also supports this supposition. Another highly active phenylurea derivative thidiazuron also enhanced RNA synthesis in leaves and retarded their senescence.
Russian Journal of Plant Physiology – Springer Journals
Published: Dec 23, 2004
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud